CompletedPhase 2

Octreotide as Palliative Therapy for Cancer-Related Bowel Obstruction That Cannot Be Removed by Surgery

United StatesStarted 1999-10

Plain-language summary

RATIONALE: Palliative therapy with octreotide may help patients who have bowel obstruction that cannot be removed by surgery to live longer and more comfortably. PURPOSE: Phase II trial to study the effectiveness of octreotide as palliative therapy in treating patients who have cancer-related bowel obstruction that cannot be removed by surgery.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

DISEASE CHARACTERISTICS: * Inoperable bowel obstruction secondary to cancer OR * Metastatic or primary abdominal cancer * Patient presents with vomiting * Percutaneous gastrostomy tube allowed PATIENT CHARACTERISTICS: Age: * Over 18 Performance status: * ECOG 0-4 Life expectancy: * Not specified Hematopoietic: * Not specified Hepatic: * Not specified Renal: * Not specified Other: * No documented hypersensitivity to octreotide * Not pregnant or nursing PRIOR CONCURRENT THERAPY: Biologic therapy: * Not specified Chemotherapy: * Prior chemotherapy allowed Endocrine therapy: * Concurrent steroids allowed Radiotherapy: * Prior radiotherapy allowed Surgery: * Not specified

Trial details

NCT IDNCT00004895

SponsorNorthwestern University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2002-10

View on ClinicalTrials.gov More Colorectal Cancer trials